Author Correction: Tau-targeting antisense oligonucleotide $MAPT_{Rx}$ in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial

Correction to: *Nature Medicine* https://doi.org/10.1038/s41591-023-02326-3. Published online 24 April 2023.

https://doi.org/10.1038/s41591-023-02639-3

Published online: 16 October 2023

Check for updates

Catherine J. Mummery, Anne Börjesson-Hanson, Daniel J. Blackburn, Everard G. B. Vijverberg, Peter Paul De Deyn, Simon Ducharme, Michael Jonsson, Anja Schneider, Juha O. Rinne, Albert C. Ludolph, Ralf Bodenschatz, Holly Kordasiewicz, Eric E. Swayze, Bethany Fitzsimmons, Laurence Mignon, Katrina M. Moore, Chris Yun, Tiffany Baumann, Dan Li, Daniel A. Norris, Rebecca Crean, Danielle L. Graham, Ellen Huang, Elena Ratti, C. Frank Bennett, Candice Junge & Roger M. Lane

In the version of this article initially published, the affiliation for Daniel Blackburn was incomplete and has been amended to read "Sheffield Teaching Hospital NHS Foundation Trust, NIHR Sheffield Clinical Research Facility and NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield, UK" in the HTML and PDF versions of the article.